[go: up one dir, main page]

MX2007013624A - Inhibidores de proteina cinasa. - Google Patents

Inhibidores de proteina cinasa.

Info

Publication number
MX2007013624A
MX2007013624A MX2007013624A MX2007013624A MX2007013624A MX 2007013624 A MX2007013624 A MX 2007013624A MX 2007013624 A MX2007013624 A MX 2007013624A MX 2007013624 A MX2007013624 A MX 2007013624A MX 2007013624 A MX2007013624 A MX 2007013624A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
disclosed
prodrugs
cancer
Prior art date
Application number
MX2007013624A
Other languages
English (en)
Inventor
David J Bearss
Hariprasad Vankayalapati
Cory L Grand
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of MX2007013624A publication Critical patent/MX2007013624A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen inhibidores de la proteina cinasa que tienen utilidad en el tratamiento de las enfermedades y condiciones mediadas por proteina cinasa, tales como el cancer; los compuestos de esta invencion tienen la estructura (I) (ver formula (I)) incluyendo estereoisomeros, profarmacos y sales farmaceuticamente aceptables de los mismos, en donde R1, R2, R3, X, Z, L2 y w son como se definen en la presente invencion; tambien se describen composiciones que contienen un compuesto de esta invencion, asi como metodos relacionados con el uso de los mismos.
MX2007013624A 2005-04-28 2006-04-28 Inhibidores de proteina cinasa. MX2007013624A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67646705P 2005-04-28 2005-04-28
PCT/US2006/016423 WO2006116733A2 (en) 2005-04-28 2006-04-28 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2007013624A true MX2007013624A (es) 2008-02-12

Family

ID=37029567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013624A MX2007013624A (es) 2005-04-28 2006-04-28 Inhibidores de proteina cinasa.

Country Status (13)

Country Link
US (1) US20090029982A1 (es)
EP (1) EP1888588A2 (es)
JP (1) JP2008539277A (es)
KR (1) KR20080020602A (es)
CN (1) CN101189239A (es)
AU (1) AU2006239236A1 (es)
BR (1) BRPI0609956A2 (es)
CA (1) CA2604284A1 (es)
IL (1) IL186744A0 (es)
MX (1) MX2007013624A (es)
NO (1) NO20075113L (es)
WO (1) WO2006116733A2 (es)
ZA (1) ZA200709269B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
KR20090130065A (ko) * 2007-04-13 2009-12-17 수퍼젠, 인크. 암 또는 과증식성 장애 치료에 유용한 Ａｘｌ 키나제 억제제
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
KR20150089099A (ko) * 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US10699235B2 (en) * 2009-05-05 2020-06-30 Oracle America, Inc. System, method and computer readable medium for placing advertisements into web pages
BR112013023266B8 (pt) 2011-03-15 2021-04-06 L Livermore Nat Security Llc inibidores da girase tricíclicos
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
ES2709003T3 (es) 2011-11-09 2019-04-12 Cancer Research Tech Ltd Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico
CN104144931B (zh) * 2012-01-27 2018-04-10 蒙特利尔大学 嘧啶并[4,5‑b]吲哚衍生物及其在造血干细胞的扩增中的应用
KR102635954B1 (ko) 2012-05-15 2024-02-13 캔써 리서치 테크놀로지 리미티드 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도
CN104804002B (zh) * 2015-04-08 2017-02-01 河南师范大学 一种9H‑嘧啶并[4,5‑b]吲哚类化合物的合成方法
CN107922926B (zh) 2015-06-05 2021-09-10 赫马魁北克公司 培养和/或使造血干细胞分化为祖细胞的方法及其用途
CN105037374B (zh) * 2015-07-14 2017-04-12 吉林大学 N‑丁基‑9H‑嘧啶并[4,5‑b]吲哚‑2‑甲酰胺的制备方法
EP3464566A4 (en) 2016-06-01 2020-01-08 Universite De Montreal SELECTION OF HUMAN HEMATOPOETIC STEM CELLS USING EPCR
CN112135618A (zh) 2018-02-20 2020-12-25 蒙特利尔大学 体内介导免疫应答的nk和dc细胞的扩增
JP2021524835A (ja) 2018-04-05 2021-09-16 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Ａｘｌキナーゼ阻害剤およびその使用
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
CN114845719A (zh) * 2019-12-18 2022-08-02 蒙特利尔大学 作为抗癌化合物的cullin 3连接蛋白kbtbd4的调节剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0882717T3 (da) * 1996-10-01 2010-12-13 Kyowa Hakko Kirin Co Ltd Nitrogenholdige heterocykliske forbindelser
KR20020032612A (ko) * 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 유도체 및 그의 의약으로서의 용도
PT1315715E (pt) * 2000-08-18 2008-10-30 Millennium Pharm Inc Derivados de quianazolina utilizados como inibidores de quinase
WO2003022214A2 (en) * 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
EP1442039A1 (en) * 2001-10-31 2004-08-04 Bayer HealthCare AG Pyrimido (4,5-b) indole derivatives
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
WO2005037825A2 (en) * 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors

Also Published As

Publication number Publication date
JP2008539277A (ja) 2008-11-13
CA2604284A1 (en) 2006-11-02
EP1888588A2 (en) 2008-02-20
WO2006116733A3 (en) 2006-12-14
IL186744A0 (en) 2008-02-09
CN101189239A (zh) 2008-05-28
NO20075113L (no) 2007-11-23
BRPI0609956A2 (pt) 2010-05-18
US20090029982A1 (en) 2009-01-29
ZA200709269B (en) 2009-01-28
WO2006116733A2 (en) 2006-11-02
AU2006239236A1 (en) 2006-11-02
KR20080020602A (ko) 2008-03-05

Similar Documents

Publication Publication Date Title
PL1678166T3 (pl) Inhibitory kinaz białkowych
MX2007013624A (es) Inhibidores de proteina cinasa.
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2012004089A (es) Inhibidores de hsp90.
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
WO2009155121A3 (en) Inhibitors of pi3 kinase
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
GB0112348D0 (en) Compounds
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
TW200630374A (en) Thiazolyldihydroindazoles
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS

Legal Events

Date Code Title Description
FG Grant or registration